Drugs / CTX-10726
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07419841 | May 2026 → Apr 2028 expected | endometrial cancer, gastroesophageal cancer, hepatocellular carcinoma, renal cell carcinoma | Compass Therapeutics | Recruiting | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2025-11-04 | Compass Therapeutics | Results Compass Therapeutics Presents Preclinical Data on CTX-10726, a Differentiated PD-1 x VEGF-A Bispecific Antibody, at the 40th Society for Immunotherapy of Cancer (SITC) Annual Meeting compasstherapeutics.com ↗
CTX-10726 demonstrated potent, simultaneous inhibition of tumor angiogenesis and PD-1-mediated immune suppression, and eliminated tumors in multiple preclinical studies. |
All press releases naming this drug 1 release
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CTX-10726 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07419841 ↗ |
| Route | Intravenous | “given as an IV infusion” NCT07419841 ↗ |